Navigation Links
Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test
Date:1/15/2014

ted data.

“This collaboration will directly benefit breast cancer patients, survivors and their physicians by providing them with two powerful integrated tools,” said André de Fusco, Cynvenio’s CEO. “The ClearID Breast Cancer test offers genomic insights from a standard blood draw analyzed by next gen sequencing. By pairing ClearID with the CollabRx Therapy Finder we can now take into account an individual patient’s molecular (tumor) data when offering the latest insights into breast cancer treatments. This is a milestone in our efforts to provide individualized breast cancer screening and surveillance.”

“The CollabRx Therapy Finder for breast cancer provides patients with an up-to-date and easily accessible tool to navigate therapy considerations that incorporate molecular data and also receive curated news that pertains to their disease,” said Thomas Mika, Chairman, President & CEO of CollabRx. “We are excited to collaborate with Cynvenio on its introduction with the goal of providing metastatic breast cancer patients with an easy to use tool to aid in treatment planning by contexualizing the state of scientific and medical research backed by sound science.”

The companion announcement from CollabRx is available on: http://www.collabrx.com.

About Cynvenio Biosystems, Inc.

Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer monitoring program and LiquidBiopsy. ClearID Breast Cancer, designed for use by patients and their physicians, is a cancer detection and monitoring program that assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide a
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cynvenio Biosystems to Present Clinical Data on Mutational Analysis of LiquidBiopsy® Tumor Samples at the 2013 ASCO Annual Meeting
2. Cynvenio Biosystems Receives CLIA Certification for its Genomic Sequencing Laboratory
3. Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
4. Fortis Offers Bachelor of Science in Nursing Degree Program to Florida Students
5. Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery
6. UH Case Medical Center Offers New Therapy for Gynecologic Cancer Patients
7. Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
8. Big Saver: Molderizer Offers 30% Mold Remediation Products Price Cut
9. Tri-Valley Sedation Dentist Dr. Endre Selmeczy Now Offers High-quality Dental Restorations
10. Berkshire Corporation Offers Live Chat For Americas Website and Shopping Cart
11. Salimetrics Offers New Saliva Collection Aid for Easy Collection of Passive Drool Samples
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)...  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), announced ... has added another internationally recognized researcher to its ... internationally recognized researcher in bio-inspired materials and bio-materials ... University, China , Professor Guan ... North Carolina, Chapel Hill. Following a postdoctoral training ...
(Date:3/30/2015)... March 30, 2015    Intrexon Corporation ... biology, and Merck Serono, the biopharmaceutical business of ... today announced an exclusive strategic collaboration and license ... T-cell (CAR-T) cancer therapies. This collaboration advances Merck ... that modulate the immune system,s natural ability to ...
(Date:3/30/2015)... LONDON , March 30, 2015 ... Patienten auf    Richmond Pharmacology ist das ... Nationalen Amyloidose-Zentrum am Royal Free Hospital in ... Phase-3-Studie zur Untersuchung eines RNAi-Therapeutikums Studienversuche an einem ... Behandlung von Transthyretin vermittelter Amyloidose entwickelt (ATTR), einer ...
(Date:3/29/2015)... 2015 As a symbol of its ... our pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to ... Berkenstock Race Team for the 2015 race season. Success ... but a strong sense of precision and attention to ... success in the quality control testing laboratory. Sponsorship of ...
Breaking Biology Technology:UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... Andrew Ryan Varian Australia Pty. Ltd., Mulgrave, 3170, Victoria, ... , The role of major, minor ... area of scientific research. In particular, research on the value of trace ... , The advent of atomic absorption ...
... Inc. , Introduction ... veterinary drugs. The use of these in food production is already ... the European Union because of a possible increased cancer-risk through long-term ... nitrofurans contamination has been found in warm-water prawns, shrimp, and chicken. ...
... in the yeast Saccharomyces cerevisiae : Detection in vivo using ... Paul Gavin# and Mark Prescott # , Ph.D , ... # Department of Biochemistry and Molecular Biology, Monash University, , ... * Technical assistance: Varian Australia Pty Ltd, Mulgrave, Victoria 3170, , ...
Cached Biology Technology:Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 2Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 3Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 4Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 5Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 6Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 7Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 8Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 9Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 10Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 11Analysis of Blood Serum on the Liberty Series II ICP-AES with the axially-viewed plasma 12Analysis of Nitrofurans Metabolites by Positive Ion Electrospray LC/MS/MS 2Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 2Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 3Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 4Cytosolic expression of Green Fluorescent Protein (GFP) and its derivatives , in the yeast Saccharomyces cerevisiae: Detection in vivo using , the Varian Cary Eclipse 5
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/19/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces its biometric payment technology, the ... aired this week on Washington DC,s ... a segment "The Next Great Thing", host Laura Evans ... pay, and ,a really big breakthrough in mobile payment.,  ...
(Date:3/16/2015)... Between 16 and 20 ... innovations in biometric identification at the CeBIT exhibition ...      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ) , ... at the forefront: the company,s all new BiometricGate ... Germany . BiometricGate is the first ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... are on the verge of unleashing the power of the ... as decades of research begins to bear fruit. Boron has ... but is now attracting fast growing research interest and investment ... to tackle cancer and infectious diseases, potentially overcoming limitations and ...
... emissions is not the only threat to the planet. Changes ... widespread use of fertilizers, are also damaging both water quality ... Brush, from Johns Hopkins University in Baltimore, USA, in her ... large estuary on the Atlantic coast of the USA. Her ...
... has consisted in the development of class antagonismsthe exploitation ... Karl Marx and Frederick Engels, The Communist Manifesto ... group well being, it also may increase the potential ... control: which individuals gain the spoils and which toil ...
Cached Biology News:European researchers harness unique properties of boron to develop new drugs and diagnostics 2European researchers harness unique properties of boron to develop new drugs and diagnostics 3Fertilizers -- a growing threat to sea life 2Caste in the colony 2
Rab1A...
... LYZL6 ( Abpromise for all ... Synthetic peptide: DWLCL AFVE SKFNISKINE ... to amino acids 46-100 of Human ... ID: 57151 ...
Request Info...
Mouse monoclonal [DJR3] to DcR1 (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 8794 SwissProtID: O14798...
Biology Products: